Institutional and infrastructure challenges for hospitals producing advanced therapies in the UK: the concept of ‘point-of-care manufacturing readiness’

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Sadin SR, Povinelli FP, Rosen R. The NASA technology push towards future space mission systems. Acta Astronautica 20, 73–77 (1989).
  Google Scholar
• 2. Wu C, Wang B, Zhang C, Wysk RA, Chen Y-W. Bioprinting: an assessment based on manufacturing readiness levels. Crit. Rev. Biotechnol. 37(3), 333–354 (2017).
  Medline CASGoogle Scholar
• 3. US Department of Defense. Manufacturing readiness level (MRL) deskbook (2018). www.dodmrl.com/MRL_Deskbook_2018.pdf
  Google Scholar
• 4. Dye E, Sturgess A, Maheshwari G et al. Examining manufacturing readiness for breakthrough drug development. AAPS PharmSciTech 17(3), 529–538 (2015).
  MedlineGoogle Scholar
• 5. Creelman B, Frivold C, Jessup S, Saxon G, Jarrahian C. Manufacturing readiness assessment for evaluation of the microneedle array patch industry: an exploration of barriers to full-scale manufacturing. Drug Deliv. Transl. Res. 12(2), 368–375 (2021).
  MedlineGoogle Scholar
• 6. Hourd P, Williams DJ. Scanning the horizon for high value-add manufacturing science: accelerating manufacturing readiness for the next generation of disruptive, high-value curative cell therapeutics. Cytotherapy 20(5), 759–767 (2018).
  MedlineGoogle Scholar
• 7. De Wilde S, Guchelaar H-J, Zandvliet ML, Meij P. Clinical development of gene- and cell-based therapies: overview of the European landscape. Mol. Ther. Methods Clin. Dev. 3, 1–7 (2016).
  Google Scholar
• 8. Pearce KF, Hildebrandt M, Greinix H et al. Regulation of advanced therapy medicinal products in Europe and the role of academia. Cytotherapy 16(3), 289–297 (2014).
  MedlineGoogle Scholar
• 9. Advanced Therapy Treatment Centres. Example risk assessment proforma for proposed activities involving Gene Therapy Medicinal Products (GTMPs) or Gene Therapy Investigational Medicinal Products (GTIMPs) (2022). www.theattcnetwork.co.uk/wp-content/uploads/2021/08/WB-GTMP-RISK-ASSESSMENT-07.21.pdf
  Google Scholar
• 10. Kaddis JS, Hanson MS, Cravens J et al. Standardized transportation of human islets: an islet cell resource center study of more than 2000 shipments. Cell Transplant. 22(7), 1101–1111 (2013).
  MedlineGoogle Scholar
• 11. Robertson K, Roberts L, Plummer D, Ede J. Complexity and workload of cytotoxic manufacturing at a regional hospital: a comparative study. J. Pharm. Pract. Res. 42(3), 193–195 (2012).
  Google Scholar
• 12. Bicudo E, Brass I, Carmichael P, Farid S. The UK’s emerging regulatory framework for point-of-care manufacture: insights from a workshop on advanced therapies. Cell & Gene Therapy Insights 7(9), 1005–1015 (2021).
  Google Scholar
• 13. Bicudo E, Brass I, Carmichael P. Point-of-care manufacture of advanced therapies: readiness measures for hospitals, companies, and regulatory agencies. (2022). Accessed in August 2022. Available at: www.ucl.ac.uk/steapp/sites/steapp/files/point-of-care_manufacture_of_advanced_therapies_fthm_policy_brief_jul_2022.pdf
  Google Scholar
• 14. Harrison RP, Rafiq QA, Medcalf N. Automating decentralized manufacturing of cell and gene therapy products. Cell Gene Ther. Insights 2(4), 489–497 (2016).
  Google Scholar
• 15. Iancu EM, Kandalaft LE. Challenges and advantages of cell therapy manufacturing under good manufacturing practices within the hospital setting. Curr. Opin. Biotechnol. 65, 233–241 (2020). •• An overview of the challenges of GMP advanced therapy medicinal products manufacture in hospitals.
  Medline CASGoogle Scholar
• 16. Sheba Online. On-site manufacture of CAR-T cells enables faster effective treatments. Sheba Online (2022). www.shebaonline.org/on-site-manufacture-of-car-t-cell-products/
  Google Scholar
• 17. Dimitropoulos G, Jafari P, De Buys Roessingh A, Hirt-Burri N, Raffoul W, Applegate LA. Burn patient care lost in good manufacturing practices? Ann. Burns Fire Disasters 29(2), 111–115 (2016).
  Medline CASGoogle Scholar
• 18. Buchholz CJ, Sanzenbacher R, Schüle S. The European hospital exemption clause: new option for gene therapy? Hum. Gene Ther. 23, 7–12 (2012).
  Medline CASGoogle Scholar
• 19. Coppens DG, Gardarsdottir H, De Bruin ML, Meij P, Leufkens HGM, Hoekman J. Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries. Regen. Med. 15(8), 2015–2028 (2020). • Examples of how the hospital exemption has been used in the EU.
  CASGoogle Scholar
• 20. Hills A, Awigena-Cook J, Genenz K et al. An assessment of the hospital exemption landscape across European member states: regulatory frameworks, use and impact. Cytotherapy 22, 772–779 (2020).
  MedlineGoogle Scholar
• 21. Medicines and Healthcare Products Regulatory Agency. Regulation (EC) n. 1394/2007 on Advanced Therapy Medicinal Products (‘the ATMP regulation’): guidance on the UK’s arrangements under the hospital exemption scheme. (1), 1–10 (2010). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/397738/Guidance_on_the_UK_s_arrangements_under_the_hospital_exemption_scheme.pdf
  Google Scholar
• 22. Thomson Reuters. Unlicensed medicinal products in the UK. 1–10 (2017). www.arnoldporter.com/~/media/files/perspectives/publications/2017/02/unlicensed-medicinal-products-in-the-uk.pdf • An overview of the UK’s Specials manufacture regulatory scheme.
  Google Scholar
• 23. Thrasher AJ. ‘Special exemptions’: should they be put on trial? Mol. Ther. 21(2), 261–262 (2013).
  MedlineGoogle Scholar
• 24. Viganò M, Giordano R, Lazzari L. Challenges of running a GMP facility for regenerative medicine in a public hospital. Regen. Med. 12(7), 803–813 (2017).
  CASGoogle Scholar
• 25. Kaiser AD, Assenmacher M, Schröder B et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther. 22, 72–78 (2015).
  Medline CASGoogle Scholar
• 26. González SL, Jendres CD, Samur EA. Evaluación de buenas prácticas de manufactura en la elaboración de fórmulas enterales en hospitales públicos de Santiago, Chile. Nutricion Hospitalaria 28(6), 2021–2026 (2013).
  MedlineGoogle Scholar
• 27. Girma M, Desale A, Hassen F, Sisay A, Tsegaye A. Survey-defined and interview-elicited challenges that faced Ethiopian government hospital laboratories as they applied ISO 15189 accreditation standards in resource-constrained settings in 2017. Am. J. Clin. Pathol. 150(4), 303–309 (2018).
  MedlineGoogle Scholar
• 28. Bicudo E. Pharmaceutical research, democracy and conspiracy: international clinical trials in local medical institutions. Routledge, London (2014).
  Google Scholar
• 29. Gardner J, Webster A, Barry J. Anticipating the clinical adoption of regenerative medicine: building institutional readiness in the UK. Regen. Med. 13(1), 29–39 (2018). •• The concept of institutional readiness.
  CASGoogle Scholar
• 30. Hodder I. The interpretation of documents and material culture. In: Handbook of Qualitative Research. Denzin NKLincoln YS (Eds). Sage, Thousand Oaks, CA, USA, 393–402 (1994).
  Google Scholar
• 31. European Parliament and Council of the EU. Regulation EC 1394/2007 of the European Parliament and the Council (2007). https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:EN:PDF
  Google Scholar
• 32. Medicines and Healthcare Products Regulatory Agency. The supply of unlicensed medicinal products (‘specials’). Guidance Note 14 (2014). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/373505/The_supply_of_unlicensed_medicinal_products__specials_.pdf
  Google Scholar
• 33. Medicines and Healthcare Products Regulatory Agency. Consultation on point of care manufacturing. www.gov.uk/government/consultations/point-of-care-consultation/consultation-on-point-of-care-manufacturing •• The Medicines and Healthcare Products Regulatory Agency’s regulatory framework proposal.
  Google Scholar
• 34. Medicines and Healthcare Products Regulatory Agency. Register of licensed manufacturing sites (2021). www.gov.uk/government/publications/human-and-veterinary-medicines-register-of-licensed-manufacturing-sites
  Google Scholar
• 35. Human Tissue Authority. Find an establishment (2022). www.hta.gov.uk/professional/establishments
  Google Scholar
• 36. R Core Team. R: a language and environment for statistical computing (2019). www.R-project.org/
  Google Scholar
• 37. Newcastle University. First patient receives NHS stem cell treatment for rare eye condition (2019). www.ncl.ac.uk/press/articles/archive/2019/12/sight-savingtreatment/
  Google Scholar
• 38. Advanced Therapy Treatment Centres. Advanced Therapies NHS readiness toolkit (2022). www.theattcnetwork.co.uk/nhs-readiness-toolkit-results?document_type=201&treatment_type=&sort=&search=&Search=Search • Practical measures for enhancing readiness in advanced therapy medicinal products in hospitals.
  Google Scholar
• 39. Black A, Caulfield D. The role of a qualified person within advanced therapy medicinal products (ATMPs). The ATTC Network (2021). https://attc-143fd.kxcdn.com/wp-content/uploads/2021/11/NAAATC_The-Role-of-the-QP.pdf
  Google Scholar
• 40. Wick J. ISO certifications in the medical field: the must-have standards. ISO Update (2020). https://isoupdate.com/general/iso-certifications-in-the-medical-field-the-must-have-standards/
  Google Scholar
• 41. Green AD, Kavanagh-Wright L, Lee GR. Investigation of the long-term yield of auditing for conformity with the ISO 15189:2012 quality standard in a hospital pathology laboratory. Pract. Lab. Med. 20(e00159), 1–6 (2020).
  Google Scholar
• 42. O’Connor L, Malkin A, Carroll B. Evaluating the impact of ISO 15189 on an Irish histopathology laboratory. Biomed. Scientist September 2016, 476–482 (2016).
  Google Scholar
• 43. Seddon J. Ten arguments against ISO 9000. Managing Service Quality 7(4), 162–168 (1997).
  Google Scholar
• 44. Wilson IG, Smye M, Wallace JC. Meta-audit of laboratory ISO accreditation inspections: measuring the old emperor's clothes. MicrobiologyOpen 51(1), 95–105 (2016).
  Google Scholar
• 45. Fact-Jacie. International standards for hematopoietic cellular therapy: product collection, processing, and administration (8th edition). (2021). www.ebmt.org/8th-edition-fact-jacie-standards
  Google Scholar
• 46. Gannon PO, Harari A, Auger A et al. Development of an optimized closed and semi-automatic protocol for good manufacturing practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment. Cytotherapy 22(12), 780–791 (2020).
  Medline CASGoogle Scholar
• 47. Petrenko Y, Chudickova M, Vackova I et al. Clinically relevant solution for the hypothermic storage and transportation of human multipotent mesenchymal stromal cells. Stem Cells Int. 11, 1–11 (2019).
  Google Scholar
• 48. Medcalf N. Centralized or decentralized manufacturing? Key business model considerations for cell therapies. Cell Gene Ther. Insights 2(1), 95–109 (2016). • An analysis of the possible models for therapy manufacture in decentralized ways.
  Google Scholar
• 49. Cell and Gene Therapy Catapult. Cell and gene therapy GMP manufacturing in the UK: capability and capacity analysis (2021). https://ct.catapult.org.uk/sites/default/files/publication/2021%20GMP%20Manufacturing%20Report.pdf
  Google Scholar
• 50. Bersenev A, Fesnak A. Place of academic GMP facilities in modern cell therapy. In: Cell Reprogramming for Immunotherapy: Methods and Protocols. Katz SGRabinovich PM (Eds). Humana Press, New York, NY, USA, 329–339 (2020).
  Google Scholar
• 51. Smethurst PA, Jolley J, Braund R et al. Rejuvenation of RBCs: validation of a manufacturing method suitable for clinical use. Transfusion 59(9), 2952–2963 (2019).
  Medline CASGoogle Scholar
• 52. Veronesi E, Murgia A, Caselli A et al. Transportation conditions for prompt use of ex vivo expanded and freshly harvested clinical-grade bone marrow mesenchymal stromal/stem cells for bone regeneration. Tissue Eng. Part C Methods 20(3), 239–251 (2014).
  Medline CASGoogle Scholar
• 53. Whiteside TL, Griffin DL, Stanson J et al. Shipping of therapeutic somatic cell products. Cytotherapy 13(2), 201–213 (2011).
  MedlineGoogle Scholar
• 54. Yu N-H, Chun SY, Ha Y-S et al. Optimal stem cell transporting conditions to maintain cell viability and characteristics. Tissue Eng. Regen. Med. 15(5), 639–647 (2018).
  Medline CASGoogle Scholar
• 55. Howard A, Chitphakdithai P, Waller EK et al. Evaluation of peripheral blood stem cell quality in products transported by traditional courier or commercial overnight shipping services. Transfusion 54(6), 1501–1507 (2014).
  MedlineGoogle Scholar
• 56. Dyson PG, Tocchetti R, Hiwase S. Validation of an alternative transport system for cryopreserved haemopoietic progenitor cells. Cytotherapy 16(4), S56 (2014).
  MedlineGoogle Scholar
• 57. Oie Y, Nozaki T, Takayanagi H et al. Development of a cell sheet transportation technique for regenerative medicine. Tissue Eng. Part C Methods 20(5), 373–382 (2014).
  Medline CASGoogle Scholar
• 58. Alliance for Regenerative Medicine. Position on hospital exemption (2017). https://alliancerm.org/sites/default/files/ARM_position_on_HE_final.pdf
  Google Scholar
• 59. Nakano LA, Cançado ELR, Chaves CE et al. A randomized crossover trial to assess therapeutic efficacy and cost reduction of acid ursodeoxycholic manufactured by the university hospital for the treatment of primary biliary cholangitis. BMC Gastroenterol. 20(1), 1–8 (2020).
  Google Scholar
• 60. Singh H, Figliola MJ, Dawson MJ et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS ONE 8(5), e64138 (2013).
  Medline CASGoogle Scholar
• 61. Van Der Loo JCM, Swaney WP, Grassman E et al. Scale-up and manufacturing of clinical-grade self-inactivating gamma-retroviral vectors by transient transfection. Gene Ther. 19(3), 246–254 (2012).
  MedlineGoogle Scholar
• 62. Juan M, Delgado J, Calvo G, Trias E, Urbano-Ispizua Á. Is hospital exemption an alternative or a bridge to European Medicines Agency for developing academic chimeric antigen receptor T-cell in Europe? Our experience with ARI-0001. Hum. Gene Ther. 32, 1004–1007 (2021).
  Medline CASGoogle Scholar
• 63. Gafni A. Alternatives to the QALY measure for economic evaluations. Support. Care Cancer 5, 105–111 (1997).
  Medline CASGoogle Scholar
• 64. Digiusto DL, Melsop K, Srivastava R, Tran C-aT. Proceedings of the first academic symposium on developing, qualifying and operating a cell and gene therapy manufacturing facility. Cytotherapy 20, 1486–1494 (2018).
  MedlineGoogle Scholar
• 65. Lanzarone E, Marconi S, Conti M et al. Hospital factory for manufacturing customised, patient-specific 3D anatomo-functional models and prostheses. In: Factories of the Future: the Italian Flagship Initiative. Tolio TCopani GTerkaj W (Eds).Springer, Cham, Switzerland, 233–254 (2019).
  Google Scholar
• 66. Webster A, Gardner J. Aligning technology and institutional readiness: the adoption of innovation. Technol. Anal. Strategic Manag. 31(10), 1229–1241 (2019).
  Google Scholar
• 67. E Bicudo, A Faulkner, P Li. Digital readinessin 3D bioprinting: software, governance and hospitals’ proto-clinical interfaces. Reg.Med. 16(3), 237–252 (2022).
  Google Scholar